Drug Approval | August 25, 2025
The company is bringing precision therapies for gynaecological cancers
The company has improved access to quality healthcare for seniors across both urban and rural areas
The facility will be positioned as a Centre of Excellence for tertiary care services
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Subscribe To Our Newsletter & Stay Updated
